Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma (Q114738626)
Jump to navigation
Jump to search
scientific article published on 23 February 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma |
scientific article published on 23 February 2017 |
Statements
Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma (English)
S. A. Fischkoff
E. Hersh
J. Weber
J. Powderly
K. Khan
A. Pavlick
W. Samlowski
S. O’Day
G. Nichol
M. Yellin
23 February 2017
16_suppl
7525-7525